Saturday, May 18, 2013 Last update: 9:34 AM
Company Tech News as it Breaks
Trade Events
AstraZeneca
News articles for AstraZeneca:
Monday, May 13, 2013
- Assessing Your Asthma is Key to Taking ControlWILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to gain control of their asthma and ... read more
Wednesday, April 10, 2013
- AstraZeneca Sponsors 2013 BIO International Convention, Apr 22 - 25, 2013, in Chicago IL, USPress Kit Materials are Available at: http://www.tradeshownews.com/events/2013-BIO-International-Convention/AstraZeneca/ Company: ... read more
Monday, March 18, 2013
- AstraZeneca to Establish Strategic R&D Center in Gaithersburg, Md; Wilmington Remains North America Commercial HeadquartersAstraZeneca (NYSE:AZN) announced today that Gaithersburg, Md., will be one of three global research and development centers to improve pipeline productivity and to establish the company as a ... read more
Thursday, February 14, 2013
- AstraZeneca Encourages Atherosclerosis Education among High Risk Patients during American Heart MonthWILMINGTON, Del., Feb. 14, 2013 /PRNewswire/ -- A survey conducted by AstraZeneca (NYSE: AZN) of more than 2000 American adults reveals that only 1 in 5 (20 percent) respondents consider themselves at increased risk for atherosclerosis-a progressive disease where plaque builds up in the arteries slowly ... read more
Tuesday, February 5, 2013
- AstraZeneca Recognized as a Top Company for Female ExecutivesThe National Association for Female Executives (NAFE) today named AstraZeneca (NYSE: AZN) one of the top 50 companies for female executives for the ... read more
Monday, December 17, 2012
- BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI PatientsAstraZeneca (NYSE: AZN) announced today that a combined panel of experts from the American College of Cardiology Foundation (ACCF) and American Heart ... read more
Wednesday, December 5, 2012
- Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX® (fulvestrant) Injection 500 mg Compared with 250 mg.1,2Today, updated overall survival (OS) data for FASLODEX® (fulvestrant) Injection in patients with hormone receptor-positive advanced breast cancer whose disease progressed or recurred following ... read more
Tuesday, December 4, 2012
- AstraZeneca to Present Key New Data for Hormone Receptor-Positive Metastatic Breast Cancer at the 35th CTRC-AACR Annual San Antonio Breast Cancer SymposiumAstraZeneca (NYSE: AZN) today announced the presentation of important new data from studies of FASLODEX® (fulvestrant) Injection at the 2012 CTRC-AACR San ... read more